01 — At a Glance
The Company That Went From ₹728 to ₹298 in a Year. Plot Twist: It Made More Money.
- 52-Week High / Low₹728 / ₹298
- Q3 FY26 Sales₹521 Cr
- Q3 FY26 PAT (Excl. Exceptional)₹17.4 Cr
- TTM EPS₹41.9
- Annualised EPS (Q1–Q3 Avg × 4)₹57.83
- Book Value / Share₹346
- Price to Book0.87x
- ROCE6.24%
- ROE (3-Yr Avg)-1.15%
- Market Cap₹2,098 Cr
Flash Summary (The Sad Version): Unichem posted Q3 FY26 PAT of ₹264 crore, but ₹275 crore came from selling land to IPCA. Strip that out and quarterly profit is ₹17.4 crore — a 70% YoY collapse. Yes, you read that correctly. The entire profit is from real estate arbitrage, not the actual business. The stock trades at 7.11x P/E and 0.87x book value. Your cousin who bought at ₹728 is now ordering conspiracy theories on YouTube instead of biryani. The question nobody asks: Why is a generic pharma company selling land instead of making medicines profitably?
02 — Introduction
The Acquisition That Looked Smart on Paper. And Then Reality Arrived.
In August 2023, IPCA Laboratories — a mid-sized but scrappy pharmaceutical company with actual operating history and cost discipline — saw an opportunity and bought 52.67% of Unichem Laboratories through an open offer at ₹440 per share. The thesis was simple enough: Unichem has US generics exposure, API capabilities via backward integration, established USFDA-approved factories, and a pile of assets (some tangible, some land). IPCA, with its proven API muscle and cost structure, would integrate Unichem, extract synergies, and unlock hidden value.
What happened instead? The stock went from ₹728 (52-week high) to ₹298 (current) in nine months. That’s a 59% evisceration. Not for any scandal. Not for a failed drug launch. But because Unichem’s core business — generic formulations sold into a brutally competitive US market — is generating minimal profits. When you actually look at the operating earnings, Q3 FY26 core profit (excluding land sale) is ₹17.4 crore on ₹521 crore revenue. That’s 3.3% net margin. Your local kirana shop has better ROIs.
Here’s where it gets messy. In December 2024, Unichem sold land to IPCA (for ₹275 crore, recognized as exceptional gain in Q3). Why? Probably to prop up balance sheet metrics, show profitability, or fund operations. It worked! The numbers look great. Your P&L statement screams success. Your stock price screams the opposite.
ICRA Rating Note (Feb 2025): ICRA upgraded Unichem’s long-term rating from A to A+ in February 2025, citing improved margin trajectory and IPCA synergies. The rating action is purely based on medium-term potential — backward integration, cost optimization, and US market tailwinds. But ratings don’t buy shares; cash flows do. And right now, Unichem’s core cash flows are anaemic.
03 — Business Model: WTF Do They Even Do?
Generic Pills for Americans. Spoiler: Americans Also Buy From Bangladesh, China, & Your Neighbor’s Garage.
Members get full access to every article.
